175 related articles for article (PubMed ID: 8695249)
21. MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas.
Zöchbauer S; Wallner J; Haider K; Depisch D; Huber H; Pirker R
Eur J Cancer; 1997 Aug; 33(9):1516-8. PubMed ID: 9337699
[TBL] [Abstract][Full Text] [Related]
22. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.
Trock BJ; Leonessa F; Clarke R
J Natl Cancer Inst; 1997 Jul; 89(13):917-31. PubMed ID: 9214671
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment.
Grabellus F; Sheu SY; Tötsch M; Lehmann N; Kaiser GM; Jasani B; Taeger G; Schmid KW
J Surg Oncol; 2010 May; 101(6):465-70. PubMed ID: 20401916
[TBL] [Abstract][Full Text] [Related]
24. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
25. Imaging of multidrug resistance in cancer.
Dizdarevic S; Peters AM
Cancer Imaging; 2011 Mar; 11(1):1-8. PubMed ID: 21362586
[TBL] [Abstract][Full Text] [Related]
26. Flow cytometric analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas.
Kunikane H; Zalupski MM; Ramachandran C; KuKuruga MA; Lucas D; Ryan JR; Krishan A
Cytometry; 1997 Aug; 30(4):197-203. PubMed ID: 9298839
[TBL] [Abstract][Full Text] [Related]
27. Evaluating limited specificity of drug pumps reduced relative resistance in human MDR phenotypes.
Jongsma AP; Riethorst A; Lankelma J; Dekker H; Westerhoff HV
Eur J Biochem; 2000 Sep; 267(17):5369-77. PubMed ID: 10951194
[TBL] [Abstract][Full Text] [Related]
28. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M
Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314
[TBL] [Abstract][Full Text] [Related]
29. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
30. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy.
Citti A; Boldrini R; Inserra A; Alisi A; Pessolano R; Mastronuzzi A; Zin A; De Sio L; Rosolen A; Locatelli F; Fruci D
Int J Oncol; 2012 Jul; 41(1):117-24. PubMed ID: 22504834
[TBL] [Abstract][Full Text] [Related]
31. Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas.
Lacave R; Coulet F; Ricci S; Touboul E; Flahault A; Rateau JG; Cesari D; Lefranc JP; Bernaudin JF
Br J Cancer; 1998 Mar; 77(5):694-702. PubMed ID: 9514046
[TBL] [Abstract][Full Text] [Related]
32. MDR1 not CYP3A4 gene expression is the predominant mechanism of innate drug resistance in pediatric soft tissue sarcoma patients.
Molina-Ortiz D; Torres-Zárate C; Cárdenas-Cardós R; Palacios-Acosta JM; Hernández-Arrazola D; Shalkow-Klincovstein J; Díaz-Díaz E; Vences-Mejía A
Cancer Biomark; 2018; 22(2):317-324. PubMed ID: 29689707
[TBL] [Abstract][Full Text] [Related]
33. LHRH receptor expression in sarcomas of bone and soft tissue.
Deivaraju C; Temple HT; Block N; Robinson P; Schally AV
Horm Mol Biol Clin Investig; 2016 Nov; 28(2):105-111. PubMed ID: 27639272
[TBL] [Abstract][Full Text] [Related]
34. MDR1/P-glycoprotein expression in colorectal cancer.
Linn SC; Giaccone G
Eur J Cancer; 1995; 31A(7-8):1291-4. PubMed ID: 7577038
[TBL] [Abstract][Full Text] [Related]
35. Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias.
Beck JF; Brügger D; Brischwein K; Liu C; Bader P; Niethammer D; Gekeler V
Jpn J Cancer Res; 2001 Aug; 92(8):896-903. PubMed ID: 11509123
[TBL] [Abstract][Full Text] [Related]
36. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F
Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209
[TBL] [Abstract][Full Text] [Related]
37. Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs.
Stein U; Walther W; Wunderlich V
Eur J Cancer; 1994; 30A(10):1541-5. PubMed ID: 7833115
[TBL] [Abstract][Full Text] [Related]
38. Expression of the human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma.
Imanishi T; Abe Y; Suto R; Higaki S; Ueyama Y; Nakamura M; Tamaoki N; Fukuda H; Imai N
Tokai J Exp Clin Med; 1994 Sep; 19(1-2):39-46. PubMed ID: 7660382
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.
Wang YH; Imai Y; Shiseki M; Tanaka J; Motoji T
Leuk Res; 2018 Apr; 67():99-108. PubMed ID: 29482174
[TBL] [Abstract][Full Text] [Related]
40. Expression of multidrug resistance-related transporters in human breast carcinoma.
Kanzaki A; Toi M; Nakayama K; Bando H; Mutoh M; Uchida T; Fukumoto M; Takebayashi Y
Jpn J Cancer Res; 2001 Apr; 92(4):452-8. PubMed ID: 11346468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
